Meeting
2011 ASCO Annual Meeting
The introduction of systematic genomic testing for patients with non-small cell lung cancer (NSCLC) at Dana-Farber Cancer Institute (DFCI).
Authors
T. M. Ortiz
Dana-Farber Cancer Institute, Boston, MA
T. M. Ortiz , V. A. Joshi , S. Heon , M. Butaney , L. Chen , D. M. Jackman , D. J. Kwiatkowski , N. I. Lindeman , P. A. Janne , B. E. Johnson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer - Metastatic/Non-small Cell
Track
Lung Cancer
Sub Track
Metastatic
Citation
J Clin Oncol 29: 2011 (suppl; abstr 7517)
Abstract #
7517
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Implementation of clinical next-generation sequencing (NGS) of non-small cell lung cancer (NSCLC) to identify EGFR amplification as a potentially targetable oncogenic alteration.
First Author: Geoffrey R. Oxnard
Poster
2014 ASCO Annual Meeting
Incidence of inconsistent driver mutations between multiple lung ground-glass nodules in patients with non-small cell lung cancer.
First Author: Shengxiang Ren
Poster
2013 ASCO Annual Meeting
Randomized phase II study of neratinib with or without temsirolimus in patients (pts) with non-small cell lung cancer (NSCLC) carrying HER2-activating mutations.
First Author: Leena Gandhi
Poster
2013 ASCO Annual Meeting
Custom (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies) trial.
First Author: Giuseppe Giaccone